Statement of Principles
concerning
OSTEOPOROSIS
No. 30 of 2006
for the purposes of the
Veterans’ Entitlements Act 1986
and
Military Rehabilitation and
Compensation Act 2004
Title
1.
This Instrument may be cited
as Statement of Principles concerning osteoporosis No. 30 of 2006.
Determination
2.
The Repatriation Medical
Authority under subsection 196B(3) and (8) of the Veterans’
Entitlements Act 1986 (the VEA):
(a) revokes Instrument No. 68 of 2002; and
(b) determines in their place this Statement of Principles.
Kind of injury, disease
or death
3. (a) This Statement of Principles is
about osteoporosis and death from osteoporosis.
(b)
For the purposes of this Statement
of Principles, “osteoporosis” means a systemic disease characterised by
low bone mass and microarchitectural deterioration of bone tissue, with a
consequent increase in bone fragility and susceptibility to fracture.
Osteoporosis is considered to be present when:
(c)
Osteoporosis attracts ICD-10-AM
codes M80, M81 or M82.
(d)
In the application of this
Statement of Principles, the definition of “osteoporosis” is that given
at paragraph 3(b) above.
Basis for determining the
factors
4. On
the sound medical-scientific evidence available, the Repatriation Medical
Authority is of the view that it is more probable than not that osteoporosis
and death from osteoporosis can be related to relevant service
rendered by veterans or members of the Forces under the VEA, or members under
the Military Rehabilitation and Compensation Act 2004 (the MRCA).
Factors that must be
related to service
5. Subject
to clause 7, at least one of the factors set out in clause 6 must be related to
the relevant service rendered by the person.
Factors
6. The
factor that must exist before it can be said that, on the balance of
probabilities, osteoporosis or death from osteoporosis is
connected with the circumstances of a person’s relevant service is:
(a)
smoking at least 20 pack years of
cigarettes, or the equivalent thereof in other tobacco products, before the
clinical onset of osteoporosis and where smoking has ceased, the clinical onset
has occurred within ten years of cessation; or
(b)
for males only, drinking at least
220 kilograms of alcohol within any ten year period within the 20 years before
the clinical onset of osteoporosis; or
(c)
for females only, drinking at
least 110 kilograms of alcohol within any ten year period within the 20 years
before the clinical onset of osteoporosis; or
(d)
having chronic renal failure at
the time of clinical onset of osteoporosis; or
(e)
being treated with a drug from the
specified list before the clinical onset of osteoporosis;
(f)
having a specified endocrine
abnormality for a continuous period of at least two years within the ten years
before the clinical onset of osteoporosis; or
(g)
having rheumatoid arthritis or
ankylosing spondylitis at the time of the clinical onset of osteoporosis; or
(h)
having multiple
myeloma, lymphoma or systemic mastocytosis at the time of the clinical onset of
osteoporosis; or
(i)
undergoing solid organ or bone
marrow transplantation before the clinical onset of osteoporosis; or
(j)
having a specified
gastrointestinal disease for a continuous period of at least the one year
before the clinical onset of osteoporosis; or
(k)
having anorexia nervosa before the
clinical onset of osteoporosis; or
(l)
being immobile for a continuous
period of at least 120 days within the one year before the clinical onset of
osteoporosis; or
(m)
having an altered dietary pattern
resulting in a decrease in average daily calcium intake to 400 mg/day or less,
for a period of at least two years before age 20 years, or for a period of at
least seven years after age 20 years, or the equivalent combination thereof,
before the clinical onset of osteoporosis; or
(n)
having a BMI of less
than 20 for a continuous period of at least four years within the ten years
before the clinical onset of osteoporosis; or
(o)
an inability to undertake any
physical activity greater than three METs for at least the ten years before the
clinical onset of osteoporosis; or
(p)
having acquired
vitamin D deficiency for at least two years within the ten years before the
clinical onset of osteoporosis; or
(q)
consuming at least 7.5 milligrams
per day of Vitamin A over a period of at least two years within the ten years
before the clinical onset of osteoporosis; or
(r)
having a severe vitamin C
deficiency within the ten years before the clinical onset of osteoporosis; or
(s)
being exposed to cadmium at levels
sufficient to cause renal damage before the clinical onset of osteoporosis; or
(t)
having iron overload at the time
of clinical onset of osteoporosis; or
(u)
smoking at least 20 pack years of
cigarettes, or the equivalent thereof in other tobacco products, before the
clinical worsening of osteoporosis and where smoking has ceased, the clinical
worsening has occurred within ten years of cessation; or
(v)
for males only, drinking at least
220 kilograms of alcohol within any ten year period within the 20 years before
the clinical worsening of osteoporosis; or
(w)
for females only, drinking at
least 110 kilograms of alcohol within any ten year period within the 20 years
before the clinical worsening of osteoporosis; or
(x)
having chronic renal failure at
the time of clinical worsening of osteoporosis; or
(y)
being treated with a drug from the
specified list before the clinical worsening of osteoporosis;
(z)
having a specified endocrine
abnormality for a continuous period of at least two years within the ten years
before the clinical worsening of osteoporosis; or
(za) having rheumatoid arthritis
or ankylosing spondylitis at the time of the clinical worsening of
osteoporosis; or
(zb) having multiple
myeloma, lymphoma or systemic mastocytosis at the time of the clinical
worsening of osteoporosis; or
(zc) undergoing solid organ or
bone marrow transplantation before the clinical worsening of osteoporosis; or
(zd) having a
specified gastrointestinal disease for a continuous period of at least the one
year before the clinical worsening of osteoporosis; or
(ze) having anorexia nervosa
before the clinical worsening of osteoporosis; or
(zf) being immobile for a
continuous period of at least 120 days within the one year before the clinical
worsening of osteoporosis; or
(zg) having an altered dietary
pattern resulting in a decrease in average daily calcium intake to 400 mg/day
or less, for a period of at least two years before age 20 years, or for a
period of at least seven years after age 20 years, or the equivalent
combination thereof, before the clinical worsening of osteoporosis; or
(zh) having a BMI of
less than 20 for a continuous period of at least four years within the 10 years
before the clinical worsening of osteoporosis; or
(zi) an inability to undertake
any physical activity greater than three METs for at least the ten years before
the clinical worsening of osteoporosis; or
(zj) having acquired
vitamin D deficiency for at least two year within the ten years before the
clinical worsening of osteoporosis; or
(zk) consuming at least 7.5
milligrams per day of Vitamin A over a period of at least two years within the
ten years before the clinical worsening of osteoporosis; or
(zl) having a severe vitamin C
deficiency within the ten years before the clinical worsening of osteoporosis;
or
(zm) being exposed to cadmium at
levels sufficient to cause renal damage before the clinical worsening of
osteoporosis; or
(zn) having iron overload at the
time of clinical worsening of osteoporosis; or
(zo) inability to obtain
appropriate clinical management for osteoporosis.
Factors that apply only
to material contribution or aggravation
7. Paragraphs 6(u) to (zo) apply only to material
contribution to, or aggravation of, osteoporosis where the person’s osteoporosis
was suffered or contracted before or during (but not arising out of) the
person’s relevant service.
Inclusion of Statements of Principles
8.
In this Statement of
Principles if a relevant factor applies and that factor includes an injury or
disease in respect of which there is a Statement of Principles then the factors
in that last mentioned Statement of Principles apply in accordance with the
terms of that Statement of Principles as in force from time to time.
Other definitions
9.
For the purposes of this
Statement of Principles:
“a drug from the specified list” means any of the drugs
(including where those drugs are contained in preparations) listed in the
following Table of Drugs, in the specified combinations of administration, dose
level, duration of treatment, and temporality (time relationship between the
administration of the drug and the onset of the disease). Where a specified
drug has been taken for more than two years before age 20 years in the
specified combinations of administration, dose level and duration of treatment,
then no time limit between the administration of the drug and the onset of the
disease applies.
Table
of Drugs
|
Drug or Group of Drugs
|
Mode *
|
Dose
|
Minimum Duration of Treatment
|
Temporality
[number of years before the clinical onset or clinical
worsening]
|
|
prednisolone or pharmacologic equivalent
glucocorticoid
|
|
|
6 months
|
within the 2 years
|
|
³ 3
grams
|
NS
|
within the 5 years
|
|
³ 10
grams
|
NS
|
NS
|
|
corticotrophins
|
NS
|
at least weekly
|
6 months
|
within the 2 years
|
|
GnRH analogues without adequate add back therapy
|
NS
|
NS
|
6 months
|
within the 2 years
|
|
Chemotherapy for cancer
|
Not topical
|
NS
|
3 months
|
NS
|
|
Tamoxifen†
|
O
|
NS
|
60 months
|
within the 10 years
|
|
Aromatase inhibitors
|
O
|
NS
|
12 months
|
NS
|
|
Antiandrogen
therapy ‡
|
NS
|
NS
|
12 months
|
NS
|
|
Medroxyprogesterone acetate, without any oestrogen
supplementation †
|
O, IM
|
NS
|
12 months
|
within the 2 years
|
|
Methotrexate∞
|
O
|
³ 10 mg/week
|
6 months
|
within the 2 years
|
|
³ 0.6 grams
|
NS
|
|
Unfractionated heparin
|
IV, SC
|
³ 15,000 units/day
|
3 months
|
within the 2 years
|
|
Anticonvulsants
|
O
|
NS
|
24 months
|
within the 10 years
|
|
Lithium
|
O
|
NS
|
24 months
|
within the 10 years
|
|
Aluminium
|
O,
parenteral
|
Daily or most days a week
|
12 months
|
within the 2 years
|
* Abbreviations: IV = intravenous;
IM = intramuscular; SC = subcutaneous; O = oral;
Inhal. = inhalation; NS = not
specified; GnRH = Gonadotrophin Releasing Hormone; mg = milligrams.
† In premenopausal women only. ‡ In males
only. # In postmenopausal women only.
∞ Osteoporosis of the tibia only.
“add back therapy” means treatment with
agents that prevent bone loss.
“a severe vitamin C
deficiency” means symptoms of scurvy or a serum ascorbic acid level of less
than 2.5 mg/L;
“a
specified endocrine abnormality” means:
(a)
Cushing’s syndrome; or
(b)
hyperparathyroidism; or
(c)
hyperprolactinaemia; or
(d)
hypogonadism; or
(e)
thyrotoxicosis; or
(f)
Type 1 diabetes mellitus;
“a
specified gastrointestinal disease” means:
(a)
bacterial overgrowth syndrome; or
(b)
cirrhosis of the liver; or
(c)
coeliac disease; or
(d)
inflammatory bowel disease; or
(e)
pancreatic insufficiency; or
(f)
total or partial gastrectomy;
“acquired vitamin D deficiency” means having a serum 25(OH)D3 level of less
than 50 nmol/L and the deficiency is not due to hereditary causes;
“alcohol” is measured by the alcohol consumption calculations utilising the
Australian Standard of 10 grams of alcohol per standard alcoholic drink;
“anorexia
nervosa” means a mental disorder characterised by refusal to maintain a
normal minimal body weight, intense fear of becoming obese that is undiminished
by weight loss, disturbance of body image resulting in a feeling of being fat
even when extremely emaciated, and amenorrhoea (in females);
“BMI”
means body mass index and is calculated as follows:
The BMI = W/H2 where:
W is the
person’s weight in kilograms and
H is the
person’s height in metres;
“chronic
renal failure” means a glomerular filtration rate of permanently less than
60 ml/minute;
“death
from osteoporosis” in relation to a person includes death from a terminal
event or condition that was contributed to by the person’s osteoporosis;
“equivalent
combination” means a calculation where one year of exposure before age 20
years is equivalent to 3.5 years of exposure after age 20 years;
“ICD-10-AM
code” means a number assigned to a particular kind of injury or disease in
The International Statistical Classification of Diseases and Related Health
Problems, 10th revision, Australian Modification (ICD-10-AM), Fourth Edition,
effective date of 1 July 2004, copyrighted by the National Centre for
Classification in Health, Sydney, NSW, and having ISBN 1 86487 594 1;
“iron overload” means
an accumulation of excess iron in tissues and organs which has been confirmed
by elevated ferritin or transferrin saturation levels. Causes include
haemochromatosis and blood transfusions;
“MET” means a unit of measurement of the level of physical exertion. 1 MET =
3.5 ml of oxygen/kg of body weight per minute or, 1.0 kcal/kg of body weight
per hour, or resting metabolic rate;
“pack
years of cigarettes, or the equivalent thereof in other tobacco products”
means a calculation of consumption where one pack year of cigarettes equals
twenty tailor made cigarettes per day for a period of one calendar year, or
7300 cigarettes. One tailor made cigarette approximates one gram of tobacco or
one gram of cigar or pipe tobacco by weight. One pack year of tailor made
cigarettes equates to 7300 cigarettes, or 7.3 kg of smoking tobacco by weight.
Tobacco products means either cigarettes, pipe tobacco or cigars smoked, alone
or in any combination;
“relevant
service” means:
(a) eligible
war service (other than operational service) under the VEA; or
(b) defence
service (other than hazardous service) under the VEA; or
(c)
peacetime service under the MRCA;
“systemic
mastocytosis” means a mast cell hyperplasia that is generally detected in
the bone marrow, skin, gastrointestinal mucosa, liver or spleen;
“terminal
event” means the proximate or ultimate cause of death and includes:
(a) pneumonia;
(b) respiratory
failure;
(c) cardiac
arrest;
(d) circulatory
failure; or
(e)
cessation of brain function.
Application
10. This Instrument applies to all matters to which
section 120B of the VEA or section 339 of the MRCA applies.
Date of effect
11. This Instrument takes effect from 28 June 2006.
Notes to Statement of Principles concerning
osteoporosis (Instrument No. 30 of 2006)
The Statement of Principles concerning osteoporosis
(Instrument No. 30 of 2006) in force under section 196B(3) of the Veterans’
Entitlements Act 1986, as shown in this compilation is amended as indicated
in the Tables below.
Table
of Instruments
|
Title
|
Date of FRLI registration
|
Date of
commencement
|
Application, saving or
transitional provisions
|
|
Statement
of Principles concerning osteoporosis (Instrument No. 30 of 2006)
|
21 June 2006
|
28 June 2006
|
|
|
Amendment
of Statement of Principles concerning osteoporosis (Instrument No. 62 of
2006)
|
2 November 2006
|
8 November 2006
|
|
Table of Amendments
|
ad. = added or inserted am. = amended
rep. = repealed rs. = repealed and substituted
|
|
Provision affected
|
How affected
|
|
Clause 6 – paras (g), (q) (za) & (zk)...........................
|
am. Instrument No.62 of 2006
|